Compare BHRB & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHRB | DRUG |
|---|---|---|
| Founded | 1852 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 856.4M |
| IPO Year | N/A | N/A |
| Metric | BHRB | DRUG |
|---|---|---|
| Price | $63.62 | $84.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $71.67 | ★ $106.75 |
| AVG Volume (30 Days) | 72.6K | ★ 265.5K |
| Earning Date | 01-22-2026 | 02-13-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 173.76 | N/A |
| EPS | ★ 7.72 | N/A |
| Revenue | ★ $340,508,000.00 | N/A |
| Revenue This Year | $24.79 | N/A |
| Revenue Next Year | $8.99 | N/A |
| P/E Ratio | $8.30 | ★ N/A |
| Revenue Growth | ★ 46.12 | N/A |
| 52 Week Low | $47.57 | $23.18 |
| 52 Week High | $70.51 | $123.75 |
| Indicator | BHRB | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 49.60 |
| Support Level | $63.50 | $83.50 |
| Resistance Level | $67.76 | $87.58 |
| Average True Range (ATR) | 1.73 | 4.38 |
| MACD | 0.02 | -1.00 |
| Stochastic Oscillator | 22.27 | 18.63 |
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.